N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...

Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

BMO Capital analyst Kostas Biliouris has reiterated their bullish stance on PRME stock, giving a Buy rating yesterday. Kostas Biliouris has ...

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...

Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in ...

Next-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company update and news of ...

Arguably the more significant of the two pieces of news was that partnership deal. Prime Medicine announced that it had signed a strategic research collaboration and license agreement with global ...

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company ...